Morepen Laboratories Share Price Rises 15%; Secures ₹825 Crore Multi-Year CDMO Mandate from Global Pharma Major

Morepen Laboratories Limited (NSE: MOREPENLAB) has secured a significant multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at ~₹825 crore (USD 91 million) from a leading global pharmaceutical major. 

This marks one of the largest single CDMO contracts in the company’s history, highlighting its expanding global footprint in pharmaceutical manufacturing.

Supplies under the agreement are expected to begin within the next four to five months, with execution planned through the first quarter of the following financial year, subject to standard operational and regulatory approvals.

Strengthening Global Manufacturing Capabilities

The mandate reinforces Morepen’s growing stature as a reliable CDMO partner for global pharmaceutical innovators. Backed by over four decades of Active Pharmaceutical Ingredient (API) manufacturing expertise, the company has steadily built credibility across regulated markets.

Morepen’s facilities hold international accreditations, including USFDA, WHO-GMP, and EU approvals, enabling it to cater to stringent global compliance requirements. Its integrated development-to-commercial manufacturing model supports complex product scale-ups and long-term supply commitments, making it an attractive partner for structured, multi-year programmes.

Industry Trend Favours Scalable Partners

The global pharmaceutical industry is increasingly consolidating supplier networks, prioritising compliant, scalable, and dependable manufacturing platforms capable of ensuring supply continuity. This shift has opened significant opportunities for established API manufacturers with strong regulatory track records.

Morepen’s vertically integrated capabilities, combined with operational scale and consistent regulatory compliance, position it well to capture this evolving demand. The company is also evaluating further capacity enhancements and technology investments to align with its expanding CDMO opportunity pipeline.

Morepen Share Price Performance

On February 23, 2026, Morepen share price opened at ₹43.00, up from its previous close of ₹39.23. At 11:30 AM, the share price of Morepen was trading at ₹45.25, up by 15.35% on the NSE.

Also Read: Best Pharma Stocks in February 2026!

Conclusion

The ₹825 crore CDMO mandate represents a major milestone in Morepen Laboratories’ growth journey. It underscores the company’s ability to secure large-scale, multi-year global engagements while strengthening its presence in regulated markets. As pharmaceutical companies increasingly seek reliable long-term manufacturing partners, Morepen’s expertise, infrastructure, and compliance-driven approach place it in a strong position to drive sustained global expansion.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.